404 related articles for article (PubMed ID: 16125051)
21. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.
Prisant LM
Am J Med; 2008 Aug; 121(8 Suppl):S8-15. PubMed ID: 18638617
[TBL] [Abstract][Full Text] [Related]
22. RAS inhibition in hypertension.
Ibrahim MM
J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
[TBL] [Abstract][Full Text] [Related]
23. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
Deckers JW; Goedhart DM; Boersma E; Briggs A; Bertrand M; Ferrari R; Remme WJ; Fox K; Simoons ML
Eur Heart J; 2006 Apr; 27(7):796-801. PubMed ID: 16497685
[TBL] [Abstract][Full Text] [Related]
24. Antihypertensive effect of perindopril: experimental pharmacology.
Barthelmebs M; Devissaguet M; Imbs JL
Clin Exp Hypertens A; 1989; 11 Suppl 2():471-86. PubMed ID: 2691126
[TBL] [Abstract][Full Text] [Related]
25. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
26. Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?
Sambhi MP; Gavras H; Robertson JI; Smith WM
West J Med; 1993 Mar; 158(3):286-94. PubMed ID: 8460511
[TBL] [Abstract][Full Text] [Related]
27. Effect of ACE inhibition on myocardial ischaemia.
Ferrari R
Eur Heart J; 1998 Sep; 19 Suppl J():J30-5. PubMed ID: 9796838
[TBL] [Abstract][Full Text] [Related]
28. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
Waeber B
J Hypertens Suppl; 2006 May; 24(3):S19-27. PubMed ID: 16723862
[TBL] [Abstract][Full Text] [Related]
29. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
Ferrari R; Bertrand ME; Remme WJ; Simoons ML; Deckers JW; Fox KM
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1037-46. PubMed ID: 18035919
[TBL] [Abstract][Full Text] [Related]
30. Perindopril for the treatment of hypertension.
Ghiadoni L
Expert Opin Pharmacother; 2011 Jul; 12(10):1633-42. PubMed ID: 21599567
[TBL] [Abstract][Full Text] [Related]
31. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Lyle PA; Tershakovec AM; Devereux RB; Oparil S; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Wedel H
Expert Opin Emerg Drugs; 2005 Nov; 10(4):729-45. PubMed ID: 16262560
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
Papademetriou V
Am Heart J; 2009 Jun; 157(6 Suppl):S24-30. PubMed ID: 19450721
[TBL] [Abstract][Full Text] [Related]
33. Effect of the angiotensin-converting enzyme inhibitor perindopril on 24-hour blood pressure in patients with lacunar infarction: comparison between dippers and non-dippers.
Yamamoto Y; Oiwa K; Hayashi M; Ohara T; Muranishi M
Hypertens Res; 2005 Jul; 28(7):571-8. PubMed ID: 16335885
[TBL] [Abstract][Full Text] [Related]
34. [The hemostasis parameters and ACE gene polymorphism in patients with essential hypertension treated with perindopril].
Janczak-Bazan A
Ann Acad Med Stetin; 2006; 52(1):51-61; discussion 61-2. PubMed ID: 17131847
[TBL] [Abstract][Full Text] [Related]
35. The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease.
Brugts JJ; den Uil CA; Danser AH; Boersma E
Cardiology; 2009; 112(4):303-12. PubMed ID: 18832826
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease.
Fox KM; Bertrand ME; Remme WJ; Ferrari R; Simoons ML; Deckers JW;
Am Heart J; 2007 Apr; 153(4):629-35. PubMed ID: 17383303
[TBL] [Abstract][Full Text] [Related]
37. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
Ceconi C; Fox KM; Remme WJ; Simoons ML; Bertrand M; Parrinello G; Kluft C; Blann A; Cokkinos D; Ferrari R; ;
Cardiovasc Res; 2007 Jan; 73(1):237-46. PubMed ID: 17140552
[TBL] [Abstract][Full Text] [Related]
38. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
[TBL] [Abstract][Full Text] [Related]
40. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
Abassi Z; Armaly Z; Nakhoul F; Hoffman A
Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
